Tag: resolution

SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- On July 22, 2025, investors in Nutex Health Inc. (NASDAQ: NUTX) saw the price of their shares significantly fall after activist investment firm Blue Orca Capital published a critical report about Nutex and its involvement with independent dispute resolution (“IDR”) vendor HaloMD.

As Consumer Demand Surges for Lab-Tested Botanical Products, Super Speciosa Responds With a Timely Tincture Update and GMP-Backed Transparency

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

Schlieren / Zurich, Switzerland, 25 July, 2025 – Memo Therapeutics AG ("MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announced results from its Phase II clinical trial evaluating potravitug, a highly potent human BK polyomavirus (“BKPyV”)-neutralizing monoclonal antibody, for the treatment of BKPyV infection in kidney transplant recipients (“KTR”).

Study reveals millions of previously unknown variants and genomic sequences from underrepresented populations

Notice is hereby given that on the initiative and by the resolution of the Board of AB “KN Energies”, legal entity code 110648893, with the registered office at Burių str. 19, Klaipėda (hereinafter - the Company), Extraordinary General Meeting of Shareholders of the Company will be held on 18 August 2025 at 1:00 p.m. The meeting will be held in the Company’s administrative office, J. Janonio str. 6B, Klaipėda (in the hall of the meeting on the 3^rd floor).

The results of AS Tallink Grupp for the Q2 2025 will be introduced at an Investor Webinar held today at 12:00 (EEST). To participate, please join via the following link; we kindly ask participants to provide their questions latest by 11:00 am by email to: investor@tallink.ee. Further details are available in a previously published announcement.